Preview Mode Links will not work in preview mode

Investor Connect Podcast

Investor Connect is for investors interested in learning more about investing in startup and growth stage companies. Experienced investors share their experiences and advice with those who are considering an investment into startups and growth companies. It includes a podcast series of interviews with investors to inform others about the process of funding startups as well as a resource list and a discussion board.  

Topics include sourcing, analyzing, and researching companies. Other topics include valuations, terms Sheets, board of directors, board of advisors, due diligence, syndicates, venture capital, angels, angel networks, family offices, crowdfunding, exits, and more.

Investor Connect is a community program. We welcome your suggestions for speakers and topics which you can send to us through the Contact page. No registration is required to use the resources.  Discussion boards are available to post and answer questions about startups and growth company investing through which registration is required.

Investor Connect is a program under the Texas Open Angel Network which is a 501(c3) non-profit dedicated to the education around startup funding.

Disclaimer: Hall T. Martin is the Director of Investor Connect which is dedicated to the education of investors for early stage funding. All opinions expressed by Hall and podcast guests are solely their own opinions and do not reflect the opinion of Investor Connect. This podcast is for informational purposes only and should not be relied upon as a basis for investment decisions.

Jan 26, 2024

On this episode of Investor Connect, Hall T. Martin welcomes Ronan O'Hagan, President & CEO of Bectas Therapeutics Inc., a groundbreaking biotech company focused on revolutionizing precision oncology. Based in [City, State/Country], Bectas Therapeutics is committed to developing cancer therapies that target over 400,000 patients annually who do not benefit from the existing standard-of-care treatments.

Ronan O'Hagan boasts over two decades of experience in building biotech teams and businesses, contributing to the development of more than 20 Investigational New Drugs (INDs) and four approved drugs. As the President & CEO of Bectas Therapeutics, O'Hagan leads a team with a mission to provide personalized cancer therapies, increasing the probability of success by fivefold and significantly reducing both cost and time in clinical development. The Bectas advisory board includes luminaries such as Dr. James Allison, a Nobel Laureate for his work in immune oncology, and Dr. Keith Flaherty, a serial entrepreneur in precision oncology.

Bectas Therapeutics Inc. focuses on developing cancer therapies tailored for patients who do not benefit from existing standard treatments, a population exceeding 400,000 individuals annually. Their precision approach ensures each patient receives the right drug for their specific cancer, significantly improving the chances of success and reducing costs and time in clinical development.

Ronan discusses the company's precision cancer therapies, leveraging human patient data. Bectas aims to bring Best-In-Class therapies with a unique blood-based biomarker, promising rapid value creation and potential early exits for investors. O'Hagan emphasizes the significance of clinical proof of concept and highlights the company's mission-driven approach to cancer health equity.

Connect with Ronan O'Hagan and Bectas Therapeutics: LinkedIn: Ronan O'Hagan; Twitter: @ohaganr



For more episodes from Investor Connect, please visit the site at:  

Check out our other podcasts here: 
For Investors check out: 
For Startups check out: 
For eGuides check out: https:/_/ 
For upcoming Events, check out  

For Feedback please contact   

Please follow, share, and leave a review.

Music courtesy of Bensound.